Journal
Naunyn-Schmiedeberg's archives of pharmacology
Publication Date
9-1-2020
Volume
393
Issue
9
First Page
1573
Last Page
1580
Document Type
Open Access Publication
DOI
10.1007/s00210-020-01886-2
Rights and Permissions
Molderings, G.J., Dumoulin, F.L., Homann, J. et al. Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness. Naunyn-Schmiedeberg's Arch Pharmacol 393, 1573–1580 (2020). https://doi.org/10.1007/s00210-020-01886-2 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Recommended Citation
Molderings, G J; Weinstock, L B; and et al., "Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: Risk for serum sickness." Naunyn-Schmiedeberg's archives of pharmacology. 393, 9. 1573 - 1580. (2020).
https://digitalcommons.wustl.edu/oa_4/1164
Additional Links
Supplemental material is available for this article at publisher site.
